<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00484874</url>
  </required_header>
  <id_info>
    <org_study_id>J0703</org_study_id>
    <secondary_id>NA_00005743</secondary_id>
    <nct_id>NCT00484874</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma</brief_title>
  <official_title>A Phase I/II Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find the highest safe dose of Iodine-131 Tositumomab
      (Bexxar®) that can be given to patients who have relapsed/refractory Hodgkin's lymphoma, what
      side effects these patients get when they take Bexxar® and if Bexxar® is effective in
      treating relapsed/refractory Hodgkin's lymphoma. Bexxar® works by delivering doses of
      radiation to cancer cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One third of patients with Hodgkin's lymphoma (HL) do not respond to or have their disease
      come back after their first therapy. These patients often then receive high-dose chemotherapy
      and blood or marrow transplant. Despite high response rates after transplant, a significant
      number, 26-65%, of these patients have their disease come back again. After transplant,
      therapy options are limited and alternative therapies for patients with HL who have relapsed
      post-transplant or who are ineligible for transplant are needed. Based on recent studies
      about how HL develops and good results of patient studies evaluating the use of the unlabeled
      anti-CD20 antibody Rituximab in HL, we think that radioimmunotherapy (RIT) with I-131
      Tositumomab(Bexxar®) will be an effective alternative therapy in patients with
      relapsed/refractory HL who are post or ineligible for transplant.

      The rationale for the use of RIT in cancer is that radiolabeled monoclonal antibodies will
      specifically target and irradiate tumor cells but not normal tissues. The specific tumor
      targeting of RIT theoretically allows higher doses of radiation to be delivered to tumor as
      compared to external beam radiation because the effects of the radiation on normal tissues is
      less with RIT. Iodine-131 Tositumomab (Bexxar®) was approved by the FDA for another type of
      lymphoma in 2003. The antibody (Tositumomab) recognizes and attaches to a protein on lymphoma
      cells and can kill these cells. The radioisotope (I-131) can help the antibody kill cells
      better.

      Iodine-131 Tositumomab (Bexxar®) is given through a vein in the arm. Iodine-131 Tositumomab
      (Bexxar®) is given in an outpatient setting.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Non-myeloablative Maximum Tolerated Dose of I-131 Tositumomab That Can be Given to Patients With Relapsed/Refractory Hodgkin's Lymphoma.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall and Complete Response Rates</measure>
    <time_frame>12 weeks post therapy</time_frame>
    <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CTI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Time to Progression Following I-131 Tositumomab Therapy.</measure>
    <time_frame>From time measurement criteria are met for response until first date that recurrent or progressive disease is objectively documented, assessed up to 5 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Visualization of Hodgkin's Lymphoma With I-131 Tositumomab Imaging and Tumor Radiation Absorbed Dose</measure>
    <time_frame>up to 1 week post-intervention</time_frame>
    <description>Percentage of participants with visualized I-131 uptake.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Hodgkin's Disease</condition>
  <arm_group>
    <arm_group_label>A Single Dose of I-131 Tositumomab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>I-131 Tositumomab therapeutic regimen given to patients with relapsed/refractory Hodgkin's lymphoma who have or have not undergone transplant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>I-131 Tositumomab therapeutic regimen</intervention_name>
    <description>Tositumomab and I-131 tositumomab are given intravenously. A test dose is given followed by a larger treatment dose.</description>
    <arm_group_label>A Single Dose of I-131 Tositumomab</arm_group_label>
    <other_name>Brand name: Bexxar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy-proven Hodgkin's lymphoma that is relapsed or refractory and the patient has
             previously had a transplant or is ineligible for transplant

          -  All stages and histologic subtypes of Hodgkin's lymphoma

          -  Malignant cells may be CD20+ or CD20-

          -  May have previously had either a non-myeloablative or myeloablative allogeneic or
             autologous stem cell transplant

          -  If prior history of greater than 1 transplant, eligible if other entry criteria are
             met

          -  No upper limit on the amount of prior chemotherapy

          -  Must be at least 4 weeks out from their most recent chemotherapy or radiation therapy,
             6 weeks if the last regimen included BCNU, or mitomycin

          -  Age 18 or greater

          -  Karnofsky performance status ≥ 60

          -  Organ and marrow function within 4 weeks of registration on the protocol as defined
             below:

          -  Leukocytes &gt;2,000/mm3

          -  Absolute neutrophil count &gt;1,000/ mm3

          -  Platelets &gt;75,000/ mm3

          -  Hemoglobin &gt;7 g/dL

          -  Creatinine &lt;2.5 mg/dL

          -  Less than 25% bone marrow involvement with Hodgkin's lymphoma within 4 weeks of
             registration on the protocol

          -  If female, not pregnant or breast feeding

          -  Ability to understand and the willingness to sign a written informed consent document

          -  At least one measurable target lesion, measuring 1.5 cm in at least one dimension by
             standard CT imaging which is FDG -avid on PET/CT.

          -  2-year expected survival from other diseases

        Exclusion Criteria:

          -  Receiving any other investigational agents at the same time

          -  Hypocellular bone marrow (less than or equal to 10% cellularity) or marked decrease in
             any one (or more) hematopoietic precursor within 4 weeks of registration on the
             protocol

          -  Inability to follow basic radiation safety precautions

          -  Active infections requiring intravenous antibiotics until after resolution of the
             infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard L Wahl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Medical Institutions</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 8, 2007</study_first_submitted>
  <study_first_submitted_qc>June 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2007</study_first_posted>
  <results_first_submitted>October 14, 2016</results_first_submitted>
  <results_first_submitted_qc>July 31, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 1, 2018</results_first_posted>
  <last_update_submitted>July 31, 2018</last_update_submitted>
  <last_update_submitted_qc>July 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hodgkin's lymphoma</keyword>
  <keyword>Radioimmunotherapy</keyword>
  <keyword>Bexxar</keyword>
  <keyword>I-131 Tositumomab</keyword>
  <keyword>Safety</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Nuclear Medicine</keyword>
  <keyword>Monoclonal antibody</keyword>
  <keyword>Radiolabeled</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iodine-131 anti-B1 antibody</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>A Single Dose of I-131 Tositumomab</title>
          <description>I-131 Tositumomab therapeutic regimen given to patients with relapsed/refractory Hodgkin's lymphoma who have or have not undergone transplant.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>A Single Dose of I-131 Tositumomab</title>
          <description>I-131 Tositumomab therapeutic regimen given to patients with relapsed/refractory Hodgkin's lymphoma who have or have not undergone transplant.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36" lower_limit="20" upper_limit="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Post-transplant</title>
          <description>Previously received blood or marrow transplant.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Non-myeloablative Maximum Tolerated Dose of I-131 Tositumomab That Can be Given to Patients With Relapsed/Refractory Hodgkin's Lymphoma.</title>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A Single Dose of I-131 Tositumomab</title>
            <description>Non-myeloablative maximum tolerated dose of I-131 Tositumomab that can be given to patients with relapsed/refractory Hodgkin's lymphoma.
I-131 Tositumomab therapeutic regimen: Tositumomab and I-131 tositumomab are given intravenously. A test dose is given followed by a larger treatment dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Non-myeloablative Maximum Tolerated Dose of I-131 Tositumomab That Can be Given to Patients With Relapsed/Refractory Hodgkin's Lymphoma.</title>
          <units>cGy</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall and Complete Response Rates</title>
        <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CTI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
        <time_frame>12 weeks post therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A Single Dose of I-131 Tositumomab</title>
            <description>A single therapeutic dosage of 131I-tositumomab.
I-131 Tositumomab therapeutic regimen: Tositumomab and I-131 tositumomab are given intravenously. A test dose is given followed by a larger treatment dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall and Complete Response Rates</title>
          <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CTI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ORR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Progression Following I-131 Tositumomab Therapy.</title>
        <time_frame>From time measurement criteria are met for response until first date that recurrent or progressive disease is objectively documented, assessed up to 5 years.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A Single Therapeutic Dosage of 131I-tositumomab</title>
            <description>A single therapeutic dosage of 131I-tositumomab in patients who have undergone transplant.
I-131 Tositumomab therapeutic regimen: Tositumomab and I-131 tositumomab are given intravenously. A test dose is given followed by a larger treatment dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Progression Following I-131 Tositumomab Therapy.</title>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Visualization of Hodgkin's Lymphoma With I-131 Tositumomab Imaging and Tumor Radiation Absorbed Dose</title>
        <description>Percentage of participants with visualized I-131 uptake.</description>
        <time_frame>up to 1 week post-intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>A single therapeutic dosage of 131I-tositumomab.
I-131 Tositumomab therapeutic regimen: Tositumomab and I-131 tositumomab are given intravenously. A test dose is given followed by a larger treatment dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Visualization of Hodgkin's Lymphoma With I-131 Tositumomab Imaging and Tumor Radiation Absorbed Dose</title>
          <description>Percentage of participants with visualized I-131 uptake.</description>
          <units>Percentage of patients with I-131 uptake</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected up to 2 years following the administration of I-131 Tositumomab.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>A Single Dose of I-131 Tositumomab</title>
          <description>I-131 Tositumomab therapeutic regimen given to patients with relapsed/refractory Hodgkin's lymphoma who have or have not undergone transplant.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title vocab="CTCAE (3.0)">Hemoglobin Decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Platelet Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Cold Intolerance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lungm aero-digestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title vocab="CTCAE (4.0)">Hemoglobin Decreased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Platelet Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Heather Jacene, MD</name_or_title>
      <organization>Dana-Farber Cancer Institute</organization>
      <phone>617-632-3767</phone>
      <email>hjacene@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

